Title: Dexetimide
CAS Registry Number: 21888-98-2
CAS Name: (3S)-3-Phenyl-1¢-(phenylmethyl)-[3,4¢-bipiperidine]-2,6-dione
Additional Names: (S)-(+)-2-(1-benzyl-4-piperidyl)-2-phenylglutarimide; (+)-3-(1-benzyl-4-piperidyl)-3-phenylpiperidine-2,6-dione; (+)-1-benzyl-4-(2,6-dioxo-3-phenyl-3-piperidyl)piperidine; dextrobenzetimide; dexbenzetimide
Molecular Formula: C23H26N2O2
Molecular Weight: 362.46
Percent Composition: C 76.21%, H 7.23%, N 7.73%, O 8.83%
Literature References: The dextroenantiomer responsible for the pharmacological activity of racemic benzetimide, q.v. Resolution of isomers and comparative pharmacology: Janssen et al., Arzneim.-Forsch. 21, 1365 (1971). Abs config studies: van Wijngaarden et al., Life Sci. 9, part 1, 1289 (1970); Spek et al., Nature 232, 575 (1971). Clinical trials: De Smedt et al., J. Clin. Pharmacol. 10, 207 (1970).
Properties: Crystals, mp 181-183°. [a]D20 +125° (chloroform).
Melting point: mp 181-183°
Optical Rotation: [a]D20 +125° (chloroform)
Derivative Type: Hydrochloride
CAS Registry Number: 21888-96-0
Manufacturers' Codes: R-16470
Trademarks: Tremblex (Janssen)
Molecular Formula: C23H26N2O2.HCl
Molecular Weight: 398.93
Percent Composition: C 69.25%, H 6.82%, N 7.02%, O 8.02%, Cl 8.89%
Properties: Crystals, mp 270-275°. [a]D20 +125° (methanol). LD50 i.v. in rats: 45 mg/kg (Janssen).
Melting point: mp 270-275°
Optical Rotation: [a]D20 +125° (methanol)
Toxicity data: LD50 i.v. in rats: 45 mg/kg (Janssen)
Therap-Cat: Antiparkinsonian.
Keywords: Antiparkinsonian; Antimuscarinic.
Dexmedetomidine Dextran Dextran Sulfate Sodium Dextranase Dextranomer

Systematic (IUPAC) name
Clinical data
AHFS/ International Drug Names
Legal status  ?
CAS number 21888-98-2 N
ATC code N04AA08
PubChem CID 30843
IUPHAR ligand 354
ChemSpider 28615 YesY
UNII 43477QYX3D YesY
KEGG D03711 YesY
Chemical data
Formula C23H26N2O2 
Mol. mass 362.465 g/mol
 N (what is this?)  (verify)

Dexetimide is a piperidine anticholinergic. It is a muscarinic antagonist that has been used to treat neuroleptic-induced Parkinsonism. Dexetimide was discovered at Janssen Pharmaceutica in 1968.[1][2]